Umlaut.bio GmbH develops small‑molecule therapeutics that target specific tRNA modifications to influence signaling pathways involved in cancer and inflammatory diseases. The company’s approach focuses on inhibiting key steps in tRNA modification to prevent overactivation of multiple signaling molecules.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of therapeutic small molecules against RNA modifications
Development of small molecules to inhibit tRNA modifications and influence mRNA stability; therapeutic approach for cancer, autoimmune and inflammatory diseases.
Knowledge
No knowledge articles yet
Once Umlaut.bio GmbH has claimed this profile, we'll publish editorial articles and case studies here together.